In advance of this week’s earnings call, Wall Street analysts at B Riley published a note today on Chromadex and recent developments relating to Nicotinamide Riboside “NR” (FAQs) (Reviews). The following are key excerpts.

Jeff Van Sinderen & Richard Magnusen, CFA at B Riley:

“CDXC (Chromadex) recently announced three clinical studies investigating the benefits of Nicotinamide Riboside (NR).

In a development that we consider to be extremely relevant, on 2/24, CDXC announced a Phase 3 clinical study demonstrating that nutritional protocol including NR accelerates recovery in mild-to-moderate COVID-19 patients as well as improving liver health and decreasing levels of inflammatory markers.

This study built on findings of a Phase 2 clinical study published in October 2020 with the Phase 3 study reporting a recovery time improvement of 3.5 days vs. 2.7 days for Phase 2.

We remind that a preclinical study relevant to COVID in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) where Dr. Anthony Fauci is the head, is underway.

On 2/4, CDXC announced results of a clinical study under review that reported a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol including Nicotinamide Riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.

Importantly, the findings of this clinical study were consistent with previously published preclinical research showing positive effects on liver health with nutritional interventions.

On 11/17, CDXC announced the initiation of a clinical trial that will investigate the potential of NR to increase milk production among preterm mothers.

…We emphasize that CDXC has been careful to avoid making claims that are not supported by scientific studies and we expect this self-imposed discipline to continue.

That said, we believe that the favorable data from this (Phase 3) study (among others) suggest potentially broader relevance that could benefit CDXC in working with partners such as Nestle Health Science, as they aim to include the health benefits of TRU NIAGEN in their products.

…In light of the vast array of clinical data being compiled around TN and ultimately, inclusion in Nestle Health Science medical-grade beverages, one could argue that valuation comparison to fast-growing functional beverage companies or perhaps even some biopharma companies is increasingly appropriate.

…Finally, as more science around TN develops, the Nestlé partnership ramps (not to mention incremental agreements for TN) and pending IP litigation is resolved, we firmly believe that investors will benefit.”

Related:

  • FAQs on taking NAD boosting vitamin supplement Nicotinamide Riboside (NR) can be found HERE.
  • NR supplementation may have helped sufferers of these diseases & conditions (Consumer Reviews)

FOLLOW us on Twitter @RaisingNAD